Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
WOCKPHARMA
Dr. Murtaza Habil Khorakiwala · Mumbai, India · 2,564 employees
₹1,916.50
▲+1.40%Wockhardt Pharma is trading near its 52-week low despite strong revenue growth, suggesting potential undervaluation amid high P/E ratio concerns.
Exchange
NSI
Currency
INR
Day range
₹1,893.10 – ₹1,934.00
52-week range
₹1,086.70 – ₹2,422.30
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears undervalued relative to its 36.4% revenue growth, trading near the bottom of its 52-week range, despite its high P/E ratio of 146.97 suggesting potential overvaluation on earnings basis.
20.9% below the 1-year high · trend up
Hedge-fund memo
Today
Stock gained 1.40% today, trading in the lower portion of its daily range.
This week
No specific weekly trend data provided, but trading near 52-week lows.
This month
No specific monthly trend data provided, but trading near 52-week lows.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
4 headlines · 3 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| WOCKPHARMA | 311.42B | 146.97 | 4.00% | 22.01% | 36.40% |
| STAR | 98.88B | 17.79 | 20.03% | 8.56% | 11.20% |
| AJANTPHARM | 429.33B | 40.63 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory hurdles in key markets like US and Europe
Mitigation: Diversify geographic footprint and strengthen compliance processes
Pressure on profit margins due to generic competition
Mitigation: Focus on higher margin specialty formulations and vertical integration
Business intelligence
Competitive moat
Global manufacturing footprint with vertically integrated API capabilities providing cost advantages and supply chain resilience.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
FDA approvals for key ANDAs (Abbreviated New Drug Applications)
Earnings report showing margin expansion
Thesis builder
Bull case
Revenue growth continues to accelerate, driving market share gains in generic formulations globally.
Base case
Maintains steady operations with diversified product portfolio across multiple therapeutic segments.
Bear case
High valuation multiple and thin profit margins could lead to correction if growth slows.
Time horizon
12-18 months
Est. CAGR
15-20%
Entry (qual.)
Accumulate near current levels or on dips below 1800 INR
Exit (qual.)
Consider profit booking above 2200 INR or if P/E expands beyond 200
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how WOCKPHARMA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain WOCKPHARMA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Accumulate at current levels given strong revenue growth and undervaluation relative to 52-week range, but monitor for earnings improvement to justify high P/E.
MarketWatch·3d ago·Dr Reddy's underperforms competitors
Mshale·4d ago·factual update no news value
TradingView·6d ago·valuation detail neutral
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 25.39% |
| 23.19% |
| 21.50% |
| TORNTPHARM | 1.85T | 76.23 | 16.99% | 20.20% | 41.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,893.10
Resistance (day/52w high)
₹1,934.00
Volume
6,22,165
Trend
up
RSI (14)
64
MACD
bullish
MA cross
golden
50-day MA
₹1,892.46
200-day MA
₹1,498.64
vs 200-DMA
27.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.